Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2002

View Archived Issues

TRK-820 as a pharmacotherapeutic for cocaine addiction

A once-daily dose regimen of NN-2211 found to be feasible for NIDDM

Intimatan superior to dalteparin in canine model of vessel wall injury thrombosis

Bio-Technology General offers second-quarter progress report

Bicifadine as effective as codeine in treating moderate to severe postsurgical dental pain

Vitex and Pall modify Inactine collaboration

Phase III results for Provenge in prostate cancer

Enrollment completed in phase II HspE7 trial

Essential Therapeutics and Fujisawa collaborate on antibiotic drug discovery

Clearance given for FM-VP4 trial

Avanir and Medison sign research and marketing agreement for Neurodex in Israel

ANO-2, a novel cyclic peroxide, shows multifunctional antiangiogenic and antitumor activity

Doxycycline inhibits abdominal aortic aneurysm growth

FDA approves Eloxatin for advanced colorectal cancer

Proneuron expands recruitment in macrophage therapy phase I trial in spinal cord injury

INS-37217 Intranasal improves multiple perennial allergic rhinitis symptoms in phase II trial

AstraZeneca researchers identify new IBAT inhibitors for dyslipidemic conditions

New antibacterial and antiprotozoal compounds claimed by De Novo

Novel antirhinoviral compounds prepared and tested at Biota

Novel NMDA receptor antagonists disclosed in patent

Novel EGFR inhibitors in early development at Boehringer Ingelheim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...